Integrin Alpha 4 - Pipeline Review, H2 2019.

Global Markets Direct’s, ‘Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2019’, provides in depth analysis on Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Ophthalmology, Cardiovascular, Genetic Disorders, Musculoskeletal Disorders and Respiratory under development targeting Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

- The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Antisense Therapeutics Ltd

Biogen Inc

C4X Discovery Holdings Plc

Daiichi Sankyo Co Ltd

EA Pharma Co Ltd

Immunwork Inc

Morphic Holding Inc

Protagonist Therapeutics Inc ...

Antisense Therapeutics Ltd

Biogen Inc

C4X Discovery Holdings Plc

Daiichi Sankyo Co Ltd

EA Pharma Co Ltd

Immunwork Inc

Morphic Holding Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha 4 (CD49 Antigen Like Family Member D or ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development

Antisense Therapeutics Ltd

Biogen Inc

C4X Discovery Holdings Plc

Daiichi Sankyo Co Ltd

EA Pharma Co Ltd

Immunwork Inc

Morphic Holding Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles

AJM-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATL-1102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AXR-159 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ET-3764 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

natalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

natalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RAB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Antagonize Integrin alpha4 and Integrin beta7 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGA4 and ITGB7 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-5232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones

Featured News & Press Releases

Aug 08, 2019: Takeda submits NDA for SC formulation of vedolizumab to treat ulcerative colitis

Aug 01, 2019: Oral Alpha-4-Beta-7 integrin antagonist PN-943 demonstrates sustained dose-related target engagement activity in a multiple ascending dose phase 1 study

Jul 24, 2019: Phase II clinical trial in DMD on track for dosing completion

Jul 22, 2019: Takeda’s study of subcutaneous vedolizumab meets primary goal

May 24, 2019: Antisense Therapeutics: Phase II clinical trial in DMD Fully Enrolled

May 22, 2019: Entyvio (vedolizumab) approved in Japan for the treatment of patients with moderately to severely active Crohn's Disease

May 19, 2019: New Exploratory data from VARSITY, the first head-to-head ulcerative colitis biologic study which demonstrated superiority of Vedolizumab to Adalimumab in clinical remission at week 52, presented at 2019 Digestive Disease Week

May 14, 2019: Oral alpha-4-beta-7 integrin antagonist PN-943 demonstrates superior dose-related target engagement activity to PTG-100 in single ascending dose phase 1 study

May 09, 2019: U.S. Food & Drug Administration accepts Takeda's Biologics License Application for a subcutaneous formulation of Vedolizumab (Entyvio) for maintenance therapy in moderately to severely active ulcerative colitis

May 07, 2019: Biogen presents new data on TYSABRI at 71st annual meeting of the American Academy of Neurology (AAN)

May 07, 2019: Protagonist Therapeutics to present preclinical data on PN-943 at Digestive Disease Week conference 2019

Apr 04, 2019: Antisense Therapeutics provides update on its phase II clinical trial in Duchenne Muscular Dystrophy

Apr 01, 2019: European Medicines Agency accepts Takeda's Marketing Authorization Application for a subcutaneous formulation of Vedolizumab for maintenance therapy in moderately to severely active Ulcerative Colitis and Crohn's Disease

Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis

Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Antisense Therapeutics Ltd, H2 2019

Pipeline by Biogen Inc, H2 2019

Pipeline by C4X Discovery Holdings Plc, H2 2019

Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Pipeline by EA Pharma Co Ltd, H2 2019

Pipeline by Immunwork Inc, H2 2019

Pipeline by Morphic Holding Inc , H2 2019

Pipeline by Protagonist Therapeutics Inc, H2 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports